These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17605001)

  • 21. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
    Conway KA; Harper JD; Lansbury PT
    Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
    Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
    Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.
    Baba M; Nakajo S; Tu PH; Tomita T; Nakaya K; Lee VM; Trojanowski JQ; Iwatsubo T
    Am J Pathol; 1998 Apr; 152(4):879-84. PubMed ID: 9546347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
    Mehra S; Sahay S; Maji SK
    Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function.
    Tofaris GK; Razzaq A; Ghetti B; Lilley KS; Spillantini MG
    J Biol Chem; 2003 Nov; 278(45):44405-11. PubMed ID: 12923179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
    Wakabayashi K; Tanji K; Mori F; Takahashi H
    Neuropathology; 2007 Oct; 27(5):494-506. PubMed ID: 18018486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The involvement of dityrosine crosslinking in α-synuclein assembly and deposition in Lewy Bodies in Parkinson's disease.
    Al-Hilaly YK; Biasetti L; Blakeman BJ; Pollack SJ; Zibaee S; Abdul-Sada A; Thorpe JR; Xue WF; Serpell LC
    Sci Rep; 2016 Dec; 6():39171. PubMed ID: 27982082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.
    Zhou W; Milder JB; Freed CR
    J Biol Chem; 2008 Apr; 283(15):9863-70. PubMed ID: 18238775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutation in the alpha-synuclein gene and sporadic Parkinson's disease, Alzheimer's disease, and dementia with lewy bodies.
    Higuchi S; Arai H; Matsushita S; Matsui T; Kimpara T; Takeda A; Shirakura K
    Exp Neurol; 1998 Sep; 153(1):164-6. PubMed ID: 9743579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathological biochemistry of alpha-synucleinopathy.
    Iwatsubo T
    Neuropathology; 2007 Oct; 27(5):474-8. PubMed ID: 18018483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease.
    Kasen A; Houck C; Burmeister AR; Sha Q; Brundin L; Brundin P
    Neurobiol Dis; 2022 May; 166():105654. PubMed ID: 35143968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of phosphorylation in synucleinopathies: focus on Parkinson's disease.
    Cavallarin N; Vicario M; Negro A
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):471-81. PubMed ID: 20522010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. α-Synuclein Fibrils Exhibit Gain of Toxic Function, Promoting Tau Aggregation and Inhibiting Microtubule Assembly.
    Oikawa T; Nonaka T; Terada M; Tamaoka A; Hisanaga S; Hasegawa M
    J Biol Chem; 2016 Jul; 291(29):15046-56. PubMed ID: 27226637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. α-Synuclein aggregation and modulating factors.
    Paleologou KE; El-Agnaf OM
    Subcell Biochem; 2012; 65():109-64. PubMed ID: 23225002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. α-Synuclein and Parkinsonism: Updates and Future Perspectives.
    Rosborough K; Patel N; Kalia LV
    Curr Neurol Neurosci Rep; 2017 Apr; 17(4):31. PubMed ID: 28324300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients.
    Recasens A; Carballo-Carbajal I; Parent A; Bové J; Gelpi E; Tolosa E; Vila M
    Acta Neuropathol Commun; 2018 Feb; 6(1):8. PubMed ID: 29422109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyloid fibril formation of alpha-synuclein is accelerated by preformed amyloid seeds of other proteins: implications for the mechanism of transmissible conformational diseases.
    Yagi H; Kusaka E; Hongo K; Mizobata T; Kawata Y
    J Biol Chem; 2005 Nov; 280(46):38609-16. PubMed ID: 16162499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurotoxic or neuroprotective: Post-translational modifications of α-synuclein at the cross-roads of functions.
    Gadhavi J; Patel M; Bhatia D; Gupta S
    Biochimie; 2022 Jan; 192():38-50. PubMed ID: 34582997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of N-terminal Acetylation on the Aggregation of Disease-related α-synuclein Variants.
    Bell R; Castellana-Cruz M; Nene A; Thrush RJ; Xu CK; Kumita JR; Vendruscolo M
    J Mol Biol; 2023 Jan; 435(1):167825. PubMed ID: 36099961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.